BMS-554417
BMS-554417 is an orally active inhibitor of insulin receptor and insulin-like growth factor-I receptor (IGF-1R) kinases, with IC50 values of 50.6 nM and 67.9 nM, respectively. BMS-554417 blocks downstream signal transduction via the ERK and PI3K/Akt pathways. BMS-554417 induces G0-G1 cell cycle arrest, prevents cyclin D1 accumulation in the nucleus, triggers mitochondrial pathway-mediated apoptosis, promotes HER2 phosphorylation, and inhibits the proliferation and growth of cancer cells. BMS-554417 can be used in research related to colon cancer, ovarian cancer, and breast cancer.
For research use only. We do not sell to patients.
- CAS No.: 468741-42-6
- Formula: C28H30ClN7O2
- Molecular Weight:532.05
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All EGFR Isoforms
More
Biological Activity
Description
|
insulin receptor 50.6 nM (IC50) |
IGF-1R 67.9 nM (IC50) |
ERK |
PI3K |
Akt |
HER2 |
In Vitro
BMS-554417 potently and selectively inhibits recombinant insulin receptor (IC50 = 50.6 nM), IGF-IR (IC50 = 67.9 nM), and FAK (IC50 = 94.0 nM) kinases in cell-free assays, with ~5-fold selectivity over other tested kinases[1].
BMS-554417 (72 h) inhibits proliferation of multiple human tumor cell lines in a dose-dependent manner, with IC50 values ranging from 0.146 μM (RD-1) to 2.21 μM (MDA MB 231), and MCF-7 cells (IC50 = 0.22-0.34 μM) are ~18-42-fold more sensitive than OV202 cells (IC50 = 6.5-8.4 μM)[1].
BMS-554417 (5-20 μM; 1 h) inhibits basal and ligand-induced IGF-IR phosphorylation in MCF-7 and OV202 cells, and insulin-induced insulin receptor phosphorylation in MCF-7 cells, without altering total receptor protein levels[1].
BMS-554417 (5-20 μM; 1 h) inhibits ligand-induced and basal ERK1/2 and Akt (Ser473) phosphorylation in MCF-7 and OV202 cells, without affecting total ERK1/2, Akt, p38, or JNK protein levels[1].
BMS-554417, a dual IGF-IR/IR tyrosine kinase inhibitor with balanced potency against both receptors, inhibits the growth of human colon (Colo205), ovarian (OV202), and MCF-7 breast cancer cells in vitro[2].
BMS-554417 completely inhibits IGF-1R/InsR phosphorylation and increases HER2 phosphorylation (with further enhancement by EGF) in OV202 ovarian cancer cells[3].
BMS-554417 (72 h) exhibits synergistic antiproliferative activity with the panHER inhibitor BMS-599626 (HY-10251) in OV202 ovarian cancer cells[3].
BMS-554417 (5 μM; 24 h) abrogates LR3 IGF-I-induced G1 to S phase progression and nuclear accumulation of cyclin D1 in MCF-7 cells[1].
BMS-554417 (IC90 concentrations, 2.5-10 μM; 72 h) induces apoptosis in MCF-7, OV202, and Jurkat cells, with apoptosis in Jurkat cells occurring via the mitochondrial pathway (independent of death receptor signaling)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF-7 human breast cancer cells, OV202 human epithelial ovarian cancer cells
-
Concentration:5 μM (MCF-7), 20 μM (OV202)
-
Incubation Time:1 h
-
Result:Completely inhibited LR3 IGF-I-induced IGF-IR phosphorylation in MCF-7 cells to nonstimulated levels.
Completely inhibited insulin-induced insulin receptor phosphorylation in MCF-7 cells to nonstimulated levels.
Greatly reduced basal and LR3 IGF-I-stimulated IGF-IR phosphorylation in OV202 cells.
Left total IGF-IR and insulin receptor protein levels unchanged across all treatment groups.\nInhibited LR3 IGF-I-induced phosphorylation of ERK1/2 and Akt (Ser473) in MCF-7 cells to basal levels.
Inhibited insulin-induced phosphorylation of ERK1/2 and Akt (Ser473) in MCF-7 cells to basal levels.
Inhibited basal and LR3 IGF-I-stimulated phosphorylation of ERK1/2 in OV202 cells.
Inhibited basal and LR3 IGF-I-stimulated phosphorylation of Akt (Ser473) in OV202 cells.
Left total ERK1/2, Akt, p38, and JNK protein levels unchanged across all treatment groups.
-
Cell Line:MCF-7 human breast cancer cells
-
Concentration:5 μM
-
Incubation Time:24 h
-
Result:Reduced the percentage of MCF-7 cells in S phase from 45.1% (LR3 IGF-I stimulated) to 6.5%.
Dramatically reduced cyclin D1 staining intensity and nuclear localization induced by LR3 IGF-I stimulation.
-
Cell Line:MCF-7 human breast cancer cells, OV202 human epithelial ovarian cancer cells, Jurkat human T-cell leukemia cells (including variants JB-6, I2.1, 5B4, 5B2)
-
Concentration:IC90 concentrations (MCF-7, OV202); 2.5-10 μM (Jurkat); 10 μM (Jurkat pathway analysis)
-
Incubation Time:72 h
-
Result:Induced PARP-1 cleavage and nuclear fragmentation in MCF-7 and OV202 cells.
Induced dose-dependent apoptosis in Jurkat cells, with ~37% apoptotic cells at 10 μM.
Showed unaltered apoptotic response in Jurkat cells treated with death receptor pathway inhibitors (DR5:Fc, IETD(OMe)-fmk, Nok-1) or FADD-deficient I2.1 cells.
Showed markedly diminished apoptotic response in Jurkat variants overexpressing Bcl-2 (JB-6 cells) or Bcl-xL (5B4 cells).
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice[1]
-
Dosage:200 mg/kg
-
Administration:p.o.; twice daily; 14 days
-
Result:Extended time to reach target tumor volume from 19.3 days to 35.5 days.
Reduced mean tumor volume significantly compared to vehicle controls between days 17 and 28 post-implantation.
Achieved a mean serum concentration of 30.0 μM at 6 hours after administration.
Chemical Information
-
CAS No. 468741-42-6
-
Molecular Weight 532.05
-
Formula C28H30ClN7O2
-
SMILES
N(C[C@@H](O)C1=CC(Cl)=CC=C1)C2=C(C=3NC=4C(N3)=CC(=CC4C)N5CCN(CCC#N)CC5)C(=O)NC=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- BMS-554417
- 468741-42-6
- BMS554417
- BMS 554417
- Insulin Receptor
- IGF-1R
- ERK
- PI3K
- Akt
- EGFR
- Apoptosis
- mitochondrial pathway apoptosis
- IGF1R-Sal tumor xenograft
- insulin receptor
- extracellular signal-related kinase
- insulin-like growth factor-I receptor
- cyclin D1
- carcinoma cells
- G0-G1 cell cycle arrest
- phosphoinositide 3-kinase/Akt pathways
- colon cancer
- Inhibitor
- inhibitor
- inhibit